close

Register

 

 

BioPharmAnalyses is a website that provides useful information on the evolution of the biopharmaceutical sector.

Access to the databases is accessible only by subscription, news are accessible to everyone.

 

5 great reasons to subscribe to BioPharmAnalyses:

 

BioPharmAnalyses regularly updates its information bases, and adds, as soon as they appear, new information in the field of surveys, agreements, acquisitions and clinical studies.

 

By subscribing, you can access five databases and more than 10,000 detailed fact sheets on agreements, fundraising, clinical studies, redemptions and regulatory life of products. You can get a quick and concise overview of the latest news from a European biopharmaceutical company, know the details of the last key agreements or follow the latest clinical and regulatory progress of a product under development or in progress. registration in Europe.

 

By subscribing, you have immediate access to over 3000 data related to the launch or publication of clinical trial results of products from European biopharmaceutical companies.

 

By subscribing, you will know about more than 3300 agreements entered into the European biopharmaceutical sphere since January 2011.

 

By subscribing, you will know the details of more than 1000 fundraisings carried out since January 2011 by European biotechnology companies (with the details of the investors who took part in the exercise, the amount of the exercise and the planned use of the funds).

 

By subscribing, you will have access to the latest regulatory advances of over 2200 products (orphan status, favorable opinion of regulatory agencies, MA ...).

 

REGISTRATION

 

I subscribe to the entire BioPharmAnalyses website at the price of € 2,000 (excl. VAT) for 1 subscription/year.

 

Billing details

Additional information

Your order

Product Total
Subscribe - One Year  × 1 2 000,00
Subtotal 2 000,00
Tax 400,00
Total 2 400,00
  • Pay via PayPal; you can pay with your credit card if you don’t have a PayPal account.